期刊
CANCER MANAGEMENT AND RESEARCH
卷 15, 期 -, 页码 399-406出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S390499
关键词
esophageal squamous cell carcinoma; immune checkpoint inhibitor; nivolumab; postoperative treatment
类别
Esophageal cancer is a common malignancy, with esophageal squamous cell carcinoma being the predominant subtype. Effective treatment options for patients with this subtype are limited. The use of immunotherapy, specifically nivolumab, has shown promising results in the treatment of metastatic esophageal cancer. This review discusses the efficacy and safety of postoperative nivolumab and explores the potential use of immune checkpoint inhibitors in the perioperative therapy of locally advanced esophageal squamous cell carcinoma.
Esophageal cancer (EC) is the seventh most common malignancy globally. There are two main histological subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the predominant histological type of esophageal cancer worldwide and has worse prognosis than esophageal adenocarcinoma. However, effective treatment for patients with ESCC remains limited. Moreover, the risk of recurrence remains high in patients with resectable ESCC even with perioperative multidisciplinary treatment, such as chemoradiotherapy or chemotherapy. Nivolumab, a human monoclonal immunoglobulin G4 antibody that inhibits programmed cell death protein 1, has recently been identified as a potential treatment for patients with metastatic esophageal cancer based on the results of the ATTRACTION-3 and CheckMate 648 trials. The CheckMate 577 trial showed survival benefits of postoperative nivolumab monotherapy compared with placebo in patients with resectable locally advanced esophageal cancer who did not achieve a pathological complete response after preoperative chemoradiotherapy. In this review, we discuss the data on the efficacy and safety of postoperative nivolumab and share future perspectives on immune checkpoint inhibitors as perioperative therapy for patients with locally advanced ESCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据